Questions and answers on the Haemagglutination Inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - Scientific guideline
Table of contents
Based on the experience from recent evaluations of annual update applications for influenza vaccines (inactivated), both regulators and industry have requested further guidance about the regulatory requirements of HI testing as applied for the qualification of influenza seed virus preparations. Whilst some of the principles outlined below may be applicable to live attenuated influenza vaccines (LAIV), there are additional considerations towards the qualification of seed virus preparations using HI testing and hence LAIVs are outside the scope of this Q&A document.
Keywords: influenza vaccine (inactivated), Haemagglutination inhibition, seed virus
-
List item
Questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - First version (PDF/147.52 KB)
Adopted
First published: 08/11/2018
EMA/CHMP/BWP/426390/2017 -
List item
Overview of comments received on 'Questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations' (EMA/CHMP/BWP/426390/2017) - First version (PDF/104.85 KB)
First published: 08/11/2018
EMA/CHMP/BWP/652969/2018 -
List item
Draft questions and answers on the haemagglutination inhibition (HI) test for qualification of influenza vaccine (inactivated) seed preparations - First version (PDF/154.31 KB)
Draft: consultation closed
First published: 01/02/2018
Last updated: 01/02/2018
Consultation dates: 01/02/2018 to 31/07/2018
EMA/CHMP/BWP/426390/2017